Search

Your search keyword '"Lacabaratz, Christine"' showing total 235 results
Start Over Author "Lacabaratz, Christine"
235 results on '"Lacabaratz, Christine"'

2. Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)

Author

Levy, Yves, Candotti, Fabio, Centlivre, Mireille, Desvallées, Mathilde, Diallo, Alpha, Durand, Mélany, Ding, Song, Hanot, Laurent, Hardel, Lucile, Hocini, Hakim, Lacabaratz, Christine, Lelièvre, Jean-Daniel, Levoyer, Léa, Moog, Christiane, Pantaleo, Giuseppe, Paul, Stéphane, Richert, Laura, Rieux, Véronique, Surgers, Laure, Wiedemann, Aurélie, Viard, Jean-Paul, Batteux, Frédéric, Grabar, Sophie, Pollard, Hélène, Lachatre, Marie, Mercier, Noémie, Molinari, Laura, Pinoges, Loretxu, Boston, Anaïs, Boilet, Valérie, Campion, Cécilia, Delahaye, Solenne, Dembélé, Mohamed, Guillochon, Quentin, Khalil, Youssra, Soutthiphong, Anne-Aygline, Taïeb, Ludivine, Wittkop, Linda, Thiebaut, Rodolphe, Foucat, Emile, Krief, Corinne, Ribeiro, Alexandre, Rodrigues, Cécile, Decoville, Thomas, Laumond, Géraldine, Li, Li-Yun, Schmidt, Sylvie, Fenwick, Craig, Gonzalo, Tapia, Kiehl, Philippe, Ben Rayana, Raida, Bouvier, Magali, Diombera, Harouna, Mehawej, Hanane, Verlinde-Carvalho, Muriel, Zatta, Marta, Launay, Odile, Tanah, Motolete Alaba, Cheref, Kahina, Durel-Maurisse, Aurélie, Favreau, Mathilde, Grange, Pascal, Guerin, Corinne, Luong, Liem Binh, Parfait, Béatrice, Christinet, Vanessa, Hottinger, Rosemary, Sommer, Isabelle, Tommasini, Francesco, Voidey, Aline, Salazar, Andres, Cardinaud, Sylvain, Zurawski, Sandra, Zurawski, Gerard, and Tomaras, Georgia D.

Published
2024
Full Text
View/download PDF

3. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

Author

Barry, Houreratou, primary, Lhomme, Edouard, additional, Surénaud, Mathieu, additional, Nouctara, Moumini, additional, Robinson, Cynthia, additional, Bockstal, Viki, additional, Valea, Innocent, additional, Somda, Serge, additional, Tinto, Halidou, additional, Meda, Nicolas, additional, Greenwood, Brian, additional, Thiébaut, Rodolphe, additional, and Lacabaratz, Christine, additional

Published
2024
Full Text
View/download PDF

4. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Author

Lévy, Yves, Wiedemann, Aurélie, Hejblum, Boris P., Durand, Mélany, Lefebvre, Cécile, Surénaud, Mathieu, Lacabaratz, Christine, Perreau, Matthieu, Foucat, Emile, Déchenaud, Marie, Tisserand, Pascaline, Blengio, Fabiola, Hivert, Benjamin, Gauthier, Marine, Cervantes-Gonzalez, Minerva, Bachelet, Delphine, Laouénan, Cédric, Bouadma, Lila, Timsit, Jean-François, Yazdanpanah, Yazdan, Pantaleo, Giuseppe, Hocini, Hakim, and Thiébaut, Rodolphe

Published
2021
Full Text
View/download PDF

5. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Author

McShane, Christopher, Callendret, Benoit, Dincq, Stephanie, Ferrault, Camille, Chai, Siew Pin, Gyselen, Maire Paule, van Looveren, Marleen, van Ballert, Sylvia, de Cnodder, Tinne, Roza, Len, Forcheh, Chiara, Stevens, Kate, Mastrandrea, Carmela, de Ridder, Sanne, Gundluru, Rachana, Swales, Nathalie, Errijegers, Vanessa, Willems, Wouter, Roorda, Veronika, Orzabal, Nicola, Assenberg, Magdalena, Vialatte, Karine, Remblier, Frédéric, Porcar, Elodie, Ottavi, Anton, Destandau, Eugénie, Schwimmer, Christine, Moinot, Laetitia, Wallet, Cédrick, Allais, Florence, Savel, Hélène, Nedjaai, Naouel, Maugard, Anaïs, Lenzi, Nehza, Loulergue, Pierre, Bahuaud, Mathilde, Lainé, Fabrice, Laviolle, Bruno, Boissel, Nolwenn, Thébault, Elise, Vallée, David, Nicolas, Jean-François, Gilbert, Sophie, Dahel, Karima, Sagorny, Karen, Lucht, Frédéric, Paul, Stéphane, Haccourt Chanavat, Alice, Charra, Florent, Mutter, Catherine, Lambour, Monique, Muller, Caroline, Hutt-Clauss, Anne, Aranda, Olivia, Bernard, Louis, Gissot, Valérie, Hallouin-Bernard, Marie-Charlotte, Goudeau, Alain, Suzzoni, Steve, Auostin, Eva, Brick, Lysiane, Lopez-Zaragoza, Jose-Luis, Melic, Giovanna, Carvalho, Murial, Chesnel, Chrystel, Hocini, Hakim, Wiedemann, Aurélie, Hanot, Laurent, Rieux, Véronique, Puri, Adeep, Adeloye, Temitope, Boyce, Malcolm, Dennison, Jeremy, Loewenstein, Inge, Sahgal, Omar, van den Berg, Frans, Calvert, Wendy, Faldon, Mary, McClain, Bruce, Newell, Marie-Lousie, Molenberghs, Geert, Pollard, Andrew J, Launay, Odile, Lelievre, Jean-Daniel, Lacabaratz, Christine, Grande, Sophie, Goldstein, Neil, Robinson, Cynthia, Gaddah, Auguste, Bockstal, Viki, Wiedemann, Aurelie, Leyssen, Maarten, Luhn, Kerstin, Richert, Laura, Bétard, Christine, Gibani, Malick M, Clutterbuck, Elizabeth A, Snape, Matthew D, Levy, Yves, Douoguih, Macaya, and Thiebaut, Rodolphe

Published
2021
Full Text
View/download PDF

6. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques

Author

Marlin, Romain, Godot, Veronique, Cardinaud, Sylvain, Galhaut, Mathilde, Coleon, Severin, Zurawski, Sandra, Dereuddre-Bosquet, Nathalie, Cavarelli, Mariangela, Gallouët, Anne-Sophie, Maisonnasse, Pauline, Dupaty, Léa, Fenwick, Craig, Naninck, Thibaut, Lemaitre, Julien, Gomez-Pacheco, Mario, Kahlaoui, Nidhal, Contreras, Vanessa, Relouzat, Francis, Fang, Raphaël Ho Tsong, Wang, Zhiqing, Ellis, III, Jerome, Chapon, Catherine, Centlivre, Mireille, Wiedemann, Aurelie, Lacabaratz, Christine, Surenaud, Mathieu, Szurgot, Inga, Liljeström, Peter, Planas, Delphine, Bruel, Timothée, Schwartz, Olivier, Werf, Sylvie van der, Pantaleo, Giuseppe, Prague, Mélanie, Thiébaut, Rodolphe, Zurawski, Gerard, Lévy, Yves, and Grand, Roger Le

Published
2021
Full Text
View/download PDF

9. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Author

Anywaine, Zacchaeus, Barry, Houreratou, Anzala, Omu, Mutua, Gaudensia, Sirima, Sodiomon B., Eholie, Serge, Kibuuka, Hannah, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen C., Cohen, Kristen W., Shukarev, Georgi, Katwere, Michael, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Thiébaut, Rodolphe, and Douoguih, Macaya

Subjects
Immunogenetics -- Methods, Ebola virus infections -- Risk factors -- Diagnosis -- Care and treatment, Immune response -- Analysis, Ebola virus -- Identification and classification -- Control -- Prevention, Biological sciences
Abstract

Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in adolescents and children in Africa. Methods and findings In this multicentre, randomised, observer-blind, placebo-controlled Phase II study, 131 adolescents (12 to 17 years old) and 132 children (4 to 11 years old) were enrolled from Eastern and Western Africa and randomised 5:1 to receive study vaccines or placebo. Vaccine groups received intramuscular injections of Ad26.ZEBOV (5 x 10.sup.10 viral particles) and MVA-BN-Filo (1 x 10.sup.8 infectious units) 28 or 56 days apart; placebo recipients received saline. Primary outcomes were safety and tolerability. Solicited adverse events (AEs) were recorded until 7 days after each vaccination and serious AEs (SAEs) throughout the study. Secondary and exploratory outcomes were humoral immune responses (binding and neutralising Ebola virus [EBOV] glycoprotein [GP]-specific antibodies), up to 1 year after the first dose. Enrolment began on February 26, 2016, and the date of last participant last visit was November 28, 2018. Of the 263 participants enrolled, 217 (109 adolescents, 108 children) received the 2-dose regimen, and 43 (20 adolescents, 23 children) received 2 placebo doses. Median age was 14.0 (range 11 to 17) and 7.0 (range 4 to 11) years for adolescents and children, respectively. Fifty-four percent of the adolescents and 51% of the children were male. All participants were Africans, and, although there was a slight male preponderance overall, the groups were well balanced. No vaccine-related SAEs were reported; solicited AEs were mostly mild/moderate. Twenty-one days post-MVA-BN-Filo vaccination, binding antibody responses against EBOV GP were observed in 100% of vaccinees (106 adolescents, 104 children). Geometric mean concentrations tended to be higher after the 56-day interval (adolescents 13,532 ELISA units [EU]/mL, children 17,388 EU/mL) than the 28-day interval (adolescents 6,993 EU/mL, children 8,007 EU/mL). Humoral responses persisted at least up to Day 365. A limitation of the study is that the follow-up period was limited to 365 days for the majority of the participants, and so it was not possible to determine whether immune responses persisted beyond this time period. Additionally, formal statistical comparisons were not preplanned but were only performed post hoc. Conclusions The heterologous 2-dose vaccination was well tolerated in African adolescents and children with no vaccine-related SAEs. All vaccinees displayed anti-EBOV GP antibodies after the 2-dose regimen, with higher responses in the 56-day interval groups. The frequency of pyrexia after vaccine or placebo was higher in children than in adolescents. These data supported the prophylactic indication against EBOV disease in a paediatric population, as licenced in the EU. Trial registration ClinicalTrials.gov NCT02564523., Author(s): Zacchaeus Anywaine 1, Houreratou Barry 2, Omu Anzala 3, Gaudensia Mutua 3, Sodiomon B. Sirima 4, Serge Eholie 5, Hannah Kibuuka 6, Christine Bétard 7, Laura Richert 7,8, Christine [...]

Published
2022
Full Text
View/download PDF

10. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Author

Barry, Houreratou, Mutua, Gaudensia, Kibuuka, Hannah, Anywaine, Zacchaeus, Sirima, Sodiomon B., Meda, Nicolas, Anzala, Omu, Eholie, Serge, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen, Cohen, Kristen W., Shukarev, Georgi, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Douoguih, Macaya, and Thiébaut, Rodolphe

Subjects
HIV patients -- Patient outcomes, Biological sciences
Abstract

Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2 sites each in Burkina Faso, Cote d'Ivoire, and Uganda. Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end of the study. The primary endpoint was safety, and the secondary endpoint was immunogenicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were measured at baseline and at predefined time points throughout the study. The first participant was enrolled on 9 November 2015, and the date of last participant's last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs were observed among the participants. The most frequent solicited AEs were injection-site pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confidence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and 7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day interval groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817), respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vaccination after 1 year induced an anamnestic response. Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. Conclusions Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children [greater than or equal to]1 year of age. Trial registration ClinicalTrials.gov NCT02564523, Author(s): Houreratou Barry 1, Gaudensia Mutua 2, Hannah Kibuuka 3, Zacchaeus Anywaine 4, Sodiomon B. Sirima 5, Nicolas Meda 1, Omu Anzala 2, Serge Eholie 6, Christine Bétard 7, Laura [...]

Published
2021
Full Text
View/download PDF

11. Immunological efficacy of pneumococcal vaccination including the 13-valent pneumococcal vaccine in adult patients with sickle-cell disease: results of the randomized DREVAC controlled trial

Author

Melica, Giovanna, primary, Bartolucci, Pablo, additional, Audureau, Etienne, additional, Le Corvoisier, Philippe, additional, Habibi, Anoosha, additional, Gellen, Justine, additional, Selmane, Dalia, additional, Michel, Marc, additional, Lacabaratz, Christine, additional, and Levy, Yves, additional

Published
2023
Full Text
View/download PDF

12. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Author

Lévy, Yves, primary, Wiedemann, Aurélie, additional, Hejblum, Boris P., additional, Durand, Mélany, additional, Lefebvre, Cécile, additional, Surénaud, Mathieu, additional, Lacabaratz, Christine, additional, Perreau, Matthieu, additional, Foucat, Emile, additional, Déchenaud, Marie, additional, Tisserand, Pascaline, additional, Blengio, Fabiola, additional, Hivert, Benjamin, additional, Gauthier, Marine, additional, Cervantes-Gonzalez, Minerva, additional, Bachelet, Delphine, additional, Laouénan, Cédric, additional, Bouadma, Lila, additional, Timsit, Jean-François, additional, Yazdanpanah, Yazdan, additional, Pantaleo, Giuseppe, additional, Hocini, Hakim, additional, and Thiébaut, Rodolphe, additional

Published
2023
Full Text
View/download PDF

14. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial.

Author

Melica, Giovanna, Bartolucci, Pablo, Audureau, Etienne, Corvoisier, Philippe Le, Habibi, Anoosha, Gellen, Justine, Selmane, Dalia, Michel, Marc, Lacabaratz, Christine, and Levy, Yves

Subjects
STREPTOCOCCAL disease prevention, PNEUMOCOCCAL vaccines, VACCINE immunogenicity, STREPTOCOCCAL diseases, VACCINE effectiveness, RANDOMIZED controlled trials, SEROTYPES, DESCRIPTIVE statistics, RESEARCH funding, SICKLE cell anemia, DISEASE risk factors, EVALUATION, DISEASE complications, ADULTS
Abstract

Background Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD. Methods This was a randomized open-labeled phase 2 study of the immunogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD. The proportion of responders (4-fold increase in serotype-specific immunoglobulin [Ig] G antibodies) to ≥10 shared serotypes was assessed at week 8. Secondary end points were (1) geometric mean titers, (2) responders to 0–1, 2–5, 6–9, or 10–12 serotypes, (3) pneumococcal opsonophagocytic activity, and (4) response durability at weeks 24 and 96. Results In total, 128 patients were randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65). At week 8, 24.56% and 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary end point (P =.02). These numbers were 36.2% and 8.7% for opsonophagocytic activity responders (P =.002). A combined PCV13/PPSV23 strategy improved the breadth of responses to 0–1, 2–5, 6–9, or 10–12 serotypes with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group. At week 96, geometric mean titers were significantly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F). Conclusions A PCV13/PPSV23 regimen improved the breadth and magnitude of antibody responses against a large range of pneumococcal serotypes in adults with SCD. The sustainability of the immune response requires recall strategies. Clinical Trial Registration: NCT02274415 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients

Author

Wiedemann, Aurélie, Pellaton, Céline, Dekeyser, Manon, Guillaumat, Lydia, Déchenaud, Marie, Krief, Corinne, Lacabaratz, Christine, Grimbert, Philippe, Pantaleo, Giuseppe, Lévy, Yves, Durrbach, Antoine, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'From pathophysiology towards immune-basedinterventions in HIV infection' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Lausanne = University of Lausanne (UNIL), Institut Gustave Roussy (IGR), Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Henri Mondor, Service de néphrologie et transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Lausanne University Hospital, AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, Department of Nephrology [Le Kremlin-Bicêtre], Institut francilien de recherche en néphrologie et transplantation [Le Kremlin-Bicêtre] (IFRNT), Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and European Project: CoVICIS

Subjects
immunosuppressive regimen, immunocompromised, mRNA vaccine, [SDV]Life Sciences [q-bio], COVID-19, General Medicine, immune responses
Abstract

International audience; Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens.

Published
2022

16. Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection

Author

Alexandre, Marie, primary, Marlin, Romain, additional, Prague, Mélanie, additional, Coleon, Severin, additional, Kahlaoui, Nidhal, additional, Cardinaud, Sylvain, additional, Naninck, Thibaut, additional, Delache, Benoit, additional, Surenaud, Mathieu, additional, Galhaut, Mathilde, additional, Dereuddre-Bosquet, Nathalie, additional, Cavarelli, Mariangela, additional, Maisonnasse, Pauline, additional, Centlivre, Mireille, additional, Lacabaratz, Christine, additional, Wiedemann, Aurelie, additional, Zurawski, Sandra, additional, Zurawski, Gerard, additional, Schwartz, Olivier, additional, Sanders, Rogier W, additional, Le Grand, Roger, additional, Levy, Yves, additional, and Thiébaut, Rodolphe, additional

Published
2022
Full Text
View/download PDF

17. T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial

Author

Richert, Laura, primary, Lelièvre, Jean-Daniel, additional, Lacabaratz, Christine, additional, Hardel, Lucile, additional, Hocini, Hakim, additional, Wiedemann, Aurélie, additional, Lucht, Frédéric, additional, Poizot-Martin, Isabelle, additional, Bauduin, Claire, additional, Diallo, Alpha, additional, Rieux, Véronique, additional, Rouch, Elodie, additional, Surenaud, Mathieu, additional, Lefebvre, Cécile, additional, Foucat, Emile, additional, Tisserand, Pascaline, additional, Guillaumat, Lydia, additional, Durand, Mélany, additional, Hejblum, Boris, additional, Launay, Odile, additional, Thiébaut, Rodolphe, additional, and Lévy, Yves, additional

Published
2022
Full Text
View/download PDF

18. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Author

Coléon, Séverin, primary, Wiedemann, Aurélie, additional, Surénaud, Mathieu, additional, Lacabaratz, Christine, additional, Hue, Sophie, additional, Prague, Mélanie, additional, Cervantes-Gonzalez, Minerva, additional, Wang, Zhiqing, additional, Ellis, Jerome, additional, Sansoni, Amandine, additional, Pierini, Camille, additional, Bardin, Quentin, additional, Fabregue, Manon, additional, Sharkaoui, Sarah, additional, Hoest, Philippe, additional, Dupaty, Léa, additional, Picard, Florence, additional, El Hajj, Marwa, additional, Centlivre, Mireille, additional, Ghosn, Jade, additional, Thiébaut, Rodolphe, additional, Cardinaud, Sylvain, additional, Malissen, Bernard, additional, Zurawski, Gérard, additional, Zarubica, Ana, additional, Zurawski, Sandra M., additional, Godot, Véronique, additional, and Lévy, Yves, additional

Published
2022
Full Text
View/download PDF

21. NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans

Author

Wagstaffe, Helen R., primary, Anzala, Omu, additional, Kibuuka, Hannah, additional, Anywaine, Zacchaeus, additional, Sirima, Sodiomon B., additional, Thiébaut, Rodolphe, additional, Richert, Laura, additional, Levy, Yves, additional, Lacabaratz, Christine, additional, Bockstal, Viki, additional, Luhn, Kerstin, additional, Douoguih, Macaya, additional, and Goodier, Martin R., additional

Published
2022
Full Text
View/download PDF

22. Author response: Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection

Author

Alexandre, Marie, primary, Marlin, Romain, additional, Prague, Mélanie, additional, Coleon, Severin, additional, Kahlaoui, Nidhal, additional, Cardinaud, Sylvain, additional, Naninck, Thibaut, additional, Delache, Benoit, additional, Surenaud, Mathieu, additional, Galhaut, Mathilde, additional, Dereuddre-Bosquet, Nathalie, additional, Cavarelli, Mariangela, additional, Maisonnasse, Pauline, additional, Centlivre, Mireille, additional, Lacabaratz, Christine, additional, Wiedemann, Aurelie, additional, Zurawski, Sandra, additional, Zurawski, Gerard, additional, Schwartz, Olivier, additional, Sanders, Rogier W, additional, Le Grand, Roger, additional, Levy, Yves, additional, and Thiébaut, Rodolphe, additional

Published
2022
Full Text
View/download PDF

23. Profound Defect of Amphiregulin Secretion by Regulatory T Cells in the Gut of HIV-Treated Patients

Author

Tariq, Mubashira, primary, Gallien, Sébastien, additional, Surenaud, Mathieu, additional, Wiedemann, Aurélie, additional, Jean-Louis, Francette, additional, Lacabaratz, Christine, additional, Lopez Zaragoza, José Luis, additional, Zeitoun, Jean-David, additional, Ysmail-Dalhouk, Saliha, additional, Lelièvre, Jean-Daniel, additional, Lévy, Yves, additional, and Hüe, Sophie, additional

Published
2022
Full Text
View/download PDF

27. Targeting human langerin promotes HIV-1 specific humoral immune responses

Author

Kervevan, Jerome, Bouteau, Aurelie, Lanza, Juliane S., Hammoudi, Adele, Zurawski, Sandra, Surenaud, Mathieu, Dieudonne, Lydie, Bonnet, Marion, Lefebvre, Cecile, Hocini, Hakim, Marlin, Romain, Gugin, Aurelie, Hersant, Barbara, Hermeziu, Oana, Menu, Elisabeth, Lacabaratz, Christine, Lelievre, Jean-Daniel, Zurawski, Gerard, Godot, Veronique, Henri, Sandrine, Igyarto, Botond Z., Levy, Yves, Cardinaud, Sylvain, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Baylor Institute for Immunology Research (BIIR), Baylor University, Jefferson (Philadelphia University + Thomas Jefferson University), Centre d'Immunophénomique (CIPHE), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), Cardiff University, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Henri Mondor, Mucosal Immunity and Sexually Transmitted Infection Control (MISTIC), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Hôpital Albert Chenevier, This work was financially supported by the Programme Investissements d’Avenir (PIA) managed by the Agence Nationale de Recherche (ANR) under reference ANR-10-LABX-77-01 (Labex VRI) (YL, SC, JK, JSL, LD). The National Institute of Health (NIH) (NIH R01AI146420) and the Baylor Foundation (institutional support) also supported this work (BZI, AB). JK., JSL and LD received salary from the ANR (ANR-10-LABX-77)., ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), Institut Pasteur [Paris]-Université Paris Cité (UPCité), DUMENIL, Anita, and Laboratoires d'excellence - Initiative for the creation of a Vaccine Research Institute - - VRI2010 - ANR-10-LABX-0077 - LABX - VALID

Subjects
RNA viruses, Physiology, [SDV]Life Sciences [q-bio], Q1, Lymphocyte Activation, Pathology and Laboratory Medicine, Mouse models, Biochemistry, Mice, White Blood Cells, Immunodeficiency Viruses, Animal Cells, Immune Physiology, Medicine and Health Sciences, Cell differentiation, Biology (General), AIDS Vaccines, Vaccines, Innate Immune System, Immune System Proteins, T Cells, env Gene Products, Human Immunodeficiency Virus, Animal Models, [SDV] Life Sciences [q-bio], Experimental Organism Systems, Medical Microbiology, Viral Pathogens, Viruses, Infectious diseases, Cytokines, Cellular Types, Pathogens, Research Article, Medical conditions, QH301-705.5, Immune Cells, Immunology, Research and Analysis Methods, Microbiology, Antibodies, T helper cells, Model Organisms, Antigens, CD, Virology, Infectious disease control, Retroviruses, Animals, Humans, Lectins, C-Type, Antibody-Producing Cells, Microbial Pathogens, B cells, Blood Cells, Viral vaccines, Lentivirus, Organisms, HIV vaccines, Biology and Life Sciences, HIV, Proteins, Cell Biology, Molecular Development, RC581-607, Immunity, Humoral, Mannose-Binding Lectins, Langerhans Cells, Immune System, Animal Studies, HIV-1, Immunologic diseases. Allergy, Developmental Biology
Abstract

The main avenue for the development of an HIV-1 vaccine remains the induction of protective antibodies. A rationale approach is to target antigen to specific receptors on dendritic cells (DC) via fused monoclonal antibodies (mAb). In mouse and non-human primate models, targeting of skin Langerhans cells (LC) with anti-Langerin mAbs fused with HIV-1 Gag antigen drives antigen-specific humoral responses. The development of these immunization strategies in humans requires a better understanding of early immune events driven by human LC. We therefore produced anti-Langerin mAbs fused with the HIV-1 gp140z Envelope (αLC.Env). First, we show that primary skin human LC and in vitro differentiated LC induce differentiation and expansion of naïve CD4+ T cells into T follicular helper (Tfh) cells. Second, when human LC are pre-treated with αLC.Env, differentiated Tfh cells significantly promote the production of specific IgG by B cells. Strikingly, HIV-Env-specific Ig are secreted by HIV-specific memory B cells. Consistently, we found that receptors and cytokines involved in Tfh differentiation and B cell functions are upregulated by LC during their maturation and after targeting Langerin. Finally, we show that subcutaneous immunization of mice by αLC.Env induces germinal center (GC) reaction in draining lymph nodes with higher numbers of Tfh cells, Env-specific B cells, as well as specific IgG serum levels compared to mice immunized with the non-targeting Env antigen. Altogether, we provide evidence that human LC properly targeted may be licensed to efficiently induce Tfh cell and B cell responses in GC., Author summary In recent years, the place of innovative vaccines based on the induction/regulation and modulation of the immune response with the aim to elicit an integrated T- and B cell immune responses against complex antigens has emerged besides “classical” vaccine vectors. Targeting antigens to dendritic cells is a vaccine technology concept supported by more than a decade of animal models and human pre-clinical experimentation. Recent investigations in animals underscored that Langerhans cells (LC) are an important target to consider for the induction of antibody responses by DC targeting vaccine approaches. Nonetheless, the development of these immunization strategies in humans remains elusive. We therefore developed and produced an HIV vaccine candidate targeting specifically LC through the Langerin receptor. We tested the ability of our vaccine candidate of targeting LC from skin explant and of inducing in vitro the differentiation of T follicular helper (Tfh) cells. Using complementary in vitro models, we demonstrated that Tfh cells induced by human LC are functional and the targeting of LC by our vaccine candidate promotes the secretion of anti-HIV IgG by memory B cells from HIV-infected individuals. In this study human LC exhibit key cellular functions able to drive potent anti-HIV-1 humoral responses providing mechanistic evidence of the Tfh- and B cell stimulating functions of primary skin targeted LC. Finally, we demonstrated in Xcr1DTA mice the significant advantage of LC targeting for inducing Tfh and germinal center (GC)-B cells and anti-HIV-1 antibodies. Therefore, the targeting of the human Langerin receptor appears to be a promising strategy for developing efficient HIV-1 vaccine.

Published
2021

28. SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines

Author

Alexandre, Marie, primary, Marlin, Romain, additional, Prague, Mélanie, additional, Coleon, Séverin, additional, Kahlaoui, Nidhal, additional, Cardinaud, Sylvain, additional, Naninck, Thibaut, additional, Delache, Benoit, additional, Surenaud, Mathieu, additional, Galhaut, Mathilde, additional, Dereuddre-Bosquet, Nathalie, additional, Cavarelli, Mariangela, additional, Maisonnasse, Pauline, additional, Centlivre, Mireille, additional, Lacabaratz, Christine, additional, Wiedemann, Aurelie, additional, Zurawski, Sandra, additional, Zurawski, Gerard, additional, Schwartz, Olivier, additional, Sanders, Rogier W, additional, Le Grand, Roger, additional, Levy, Yves, additional, and Thiébaut, Rodolphe, additional

Published
2021
Full Text
View/download PDF

29. NPJ Vaccines

Author

Wagstaffe, Helen R., Susannini, Giada, Thiébaut, Rodolphe, Richert, Laura, Lévy, Yves, Lévy, Yves, Bockstal, Viki, Stoop, Jeroen N., Luhn, Kerstin, Douoguih, Macaya, Riley, Eleanor M, Lacabaratz, Christine, Goodier, Martin R, London School of Hygiene and Tropical Medicine (LSHTM), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and Janssen Vaccines & Prevention [Leiden]

Subjects
viruses, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

International audience; Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56(bright) NK cells. In vitro antibody-dependent responses to immobilised Ebola GP increased after dose 1, and remained elevated compared to pre-vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-γ responses remained significantly elevated at 180 days post-dose 2. Individual variation in NK cell responses were influenced by both anti-Ebola GP antibody concentrations and intrinsic interindividual differences in NK cell functional capacity. In summary, this study demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform the immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.

Published
2021

30. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment

Author

Levy, Yves, Lacabaratz, Christine, Weiss, Laurence, Viard, Jean-Paul, Goujard, Cecile, Lelievre, Jean-Daniel, Boue, Francois, Molina, Jean-Michel, Rouzioux, Christine, Avettand-Fenoel, Veronique, Croughs, Therese, Beq, Stephanie, Thiebaut, Rodolphe, Chene, Genevieve, Morre, Michel, and Delfraissy, Jean-Francois

Subjects
Interleukins -- Health aspects, T cells -- Health aspects, T cells -- Research, HIV infection -- Prevention, HIV infection -- Research, HIV infection -- Risk factors, HIV infection -- Drug therapy
Abstract

HIV infection results in [CD4.sup.+] T cell deficiency, but efficient combination antiretroviral therapy (c-ART) restores T cells and decreases morbidity and mortality. However, immune restoration by c-ART remains variable, and prolonged T cell deficiency remains in a substantial proportion of patients. In a prospective open-label phase I/IIa trial, we evaluated the safety and efficacy of administration of the T cell regulator IL-7. The trial included 13 c-ART--treated HIV-infected patients whose [CD4.sup.+] cell counts were between 100 and 400 cells/[mu]l and plasma HIV RNA levels were less than 50 copies/ml. Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 [micro]g/kg) 3 times per week over a 16-day period. rhIL-7 was well tolerated and induced a sustained increase of naive and central memory [CD4.sup.+] and [CD8.sup.+] T cells. In the highest dose group, 4 patients experienced transient increases in viral replication. However, functional assays showed that the expanded T cells responded to HIV antigen by producing IFN-[gamma] and/or IL-2. In conclusion, in lymphopenic HIV-infected patients, rhIL-7 therapy induced substantial functional and quantitative changes in T cells for 48 weeks. Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART., Introduction Infection with HIV is characterized by chronic T cell depletion and increased risk of illness and opportunistic infection. Effective treatment of HIV infection with combination antiretroviral therapy (c-ART) suppresses [...]

Published
2009

31. Modelling the response to vaccine in nonhuman primates to define SARS-CoV-2 mechanistic correlates of protection.

Author

Alexandre, Marie, Marlin, Romain, Prague, Mélanie, Coleon, Severin, Kahlaoui, Nidhal, Cardinaud, Sylvain, Naninck, Thibaut, Delache, Benoit, Surenaud, Mathieu, Galhaut, Mathilde, Dereuddre-Bosquet, Nathalie, Cavarelli, Mariangela, Maisonnasse, Pauline, Centlivre, Mireille, Lacabaratz, Christine, Wiedemann, Aurelie, Zurawski, Sandra, Zurawski, Gerard, Schwartz, Olivier, and Sanders, Rogier W.

Published
2022
Full Text
View/download PDF

32. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Author

Pollard, Andrew J, primary, Launay, Odile, additional, Lelievre, Jean-Daniel, additional, Lacabaratz, Christine, additional, Grande, Sophie, additional, Goldstein, Neil, additional, Robinson, Cynthia, additional, Gaddah, Auguste, additional, Bockstal, Viki, additional, Wiedemann, Aurelie, additional, Leyssen, Maarten, additional, Luhn, Kerstin, additional, Richert, Laura, additional, Bétard, Christine, additional, Gibani, Malick M, additional, Clutterbuck, Elizabeth A, additional, Snape, Matthew D, additional, Levy, Yves, additional, Douoguih, Macaya, additional, Thiebaut, Rodolphe, additional, McShane, Christopher, additional, Callendret, Benoit, additional, Dincq, Stephanie, additional, Ferrault, Camille, additional, Chai, Siew Pin, additional, Gyselen, Maire Paule, additional, van Looveren, Marleen, additional, van Ballert, Sylvia, additional, de Cnodder, Tinne, additional, Roza, Len, additional, Forcheh, Chiara, additional, Stevens, Kate, additional, Mastrandrea, Carmela, additional, de Ridder, Sanne, additional, Gundluru, Rachana, additional, Swales, Nathalie, additional, Errijegers, Vanessa, additional, Willems, Wouter, additional, Roorda, Veronika, additional, Orzabal, Nicola, additional, Assenberg, Magdalena, additional, Vialatte, Karine, additional, Remblier, Frédéric, additional, Porcar, Elodie, additional, Ottavi, Anton, additional, Destandau, Eugénie, additional, Schwimmer, Christine, additional, Moinot, Laetitia, additional, Wallet, Cédrick, additional, Allais, Florence, additional, Savel, Hélène, additional, Nedjaai, Naouel, additional, Maugard, Anaïs, additional, Lenzi, Nehza, additional, Loulergue, Pierre, additional, Bahuaud, Mathilde, additional, Lainé, Fabrice, additional, Laviolle, Bruno, additional, Boissel, Nolwenn, additional, Thébault, Elise, additional, Vallée, David, additional, Nicolas, Jean-François, additional, Gilbert, Sophie, additional, Dahel, Karima, additional, Sagorny, Karen, additional, Lucht, Frédéric, additional, Paul, Stéphane, additional, Haccourt Chanavat, Alice, additional, Charra, Florent, additional, Mutter, Catherine, additional, Lambour, Monique, additional, Muller, Caroline, additional, Hutt-Clauss, Anne, additional, Aranda, Olivia, additional, Bernard, Louis, additional, Gissot, Valérie, additional, Hallouin-Bernard, Marie-Charlotte, additional, Goudeau, Alain, additional, Suzzoni, Steve, additional, Auostin, Eva, additional, Brick, Lysiane, additional, Lopez-Zaragoza, Jose-Luis, additional, Melic, Giovanna, additional, Carvalho, Murial, additional, Chesnel, Chrystel, additional, Hocini, Hakim, additional, Wiedemann, Aurélie, additional, Hanot, Laurent, additional, Rieux, Véronique, additional, Puri, Adeep, additional, Adeloye, Temitope, additional, Boyce, Malcolm, additional, Dennison, Jeremy, additional, Loewenstein, Inge, additional, Sahgal, Omar, additional, van den Berg, Frans, additional, Calvert, Wendy, additional, Faldon, Mary, additional, McClain, Bruce, additional, Newell, Marie-Lousie, additional, and Molenberghs, Geert, additional

Published
2021
Full Text
View/download PDF

34. Long-lasting severe immune dysfunction in Ebola virus disease survivors

Author

Wiedemann, Aurélie, Foucat, Emile, Hocini, Hakim, Lefebvre, Cécile, Hejblum, Boris P., Durand, Mélany, Krüger, Miriam, Keita, Alpha Kabinet, Ayouba, Ahidjo, Mély, Stéphane, Fernandez, José-Carlos, Touré, Abdoulaye, Fourati, Slim, Lévy-Marchal, Claire, Raoul, Hervé, Delaporte, Eric, Koivogui, Lamine, Thiébaut, Rodolphe, Lacabaratz, Christine, Lévy, Yves, Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Santé publique, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Gamal Abdel Nasser de Conakry, Laboratoire P4 - Jean Mérieux, Centre Européen de Virologie/Immunologie-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Santé Publique [Conakry, Guinée] (INSP), Ministère de la Santé [Conakry, Guinea], CHU Henri Mondor, Pôle de Recherche Clinique [Paris] (PRC), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Bordeaux [Bordeaux], This work was supported by INSERM and by the Investissements d’Avenir program, Vaccine Research Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01., PostEboGui Study Group, ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), Bodescot, Myriam, Laboratoires d'excellence - Initiative for the creation of a Vaccine Research Institute - - VRI2010 - ANR-10-LABX-0077 - LABX - VALID, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), ANR-10-LABX-0077/10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université de Bordeaux (UB), Laboratoire P4 Jean Mérieux-Inserm [Lyon] (Unité de service 3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Européen de Recherche en Virologie et Immunologie [Lyon] (Tour Inserm CERVI), Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut national de la santé publique (INSP), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), and CHU Henri Mondor [Créteil]

Subjects
Adult, Genetic Markers, Male, [SDV.IMM] Life Sciences [q-bio]/Immunology, T-Lymphocytes, Immunology, Antibodies, Viral, Lymphocyte Activation, Antiviral Agents, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, Article, Young Adult, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, Survivors, Immunological disorders, Inflammation, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, B-Lymphocytes, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Hemorrhagic Fever, Ebola, Ebolavirus, SISTM, Immune System Diseases, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Immunoglobulin G, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Infection, Transcriptome
Abstract

Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18–25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in ‘inflammation’ and ‘antiviral’ pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of “chronic Ebola virus disease (CEVD)”., Patients who have recovered from Ebola virus can have ongoing health problems. Here, the authors show that 35 Guinean survivors of the last West African Ebola epidemic have a chronic disease with high inflammatory cytokine expression and other markers of immune activation as well as evidence of intestinal tissue damage nearly two years after their release from hospital.

Published
2020

35. Structured treatment interruptions in primary HIV-1 infection

Author

Hoen, Bruno, Lacabaratz, Christine, Charreau, Isabella, Molina, Jean-Michel, Venet, Alain, Fournier, Isabella, Burgard, Marianne, Chaix, Marie-Laure, Livrozet, Jean-Michel, Raffi, Francois, Aboulker, Jean-Pierre, and Rouzioux, Christine

Subjects
HIV infection -- Care and treatment, Immune response -- Research, Highly active antiretroviral therapy -- Health aspects, Highly active antiretroviral therapy -- Research, Health
Abstract

A study is conducted to examine whether structured treatment interruptions (STIs) can induce anti-HIV immune response and control HIV replication following discontinuation of highly active antiretroviral therapy (HAART) in patients with primary HIV infection. The results failed to establish that a significant proportion of patients with primary HIV infection could maintain suppression of viremia after a sequence of HAART/STIs followed by HAART discontinuation.

Published
2005

37. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Author

Lévy, Yves, primary, Lacabaratz, Christine, additional, Ellefsen-Lavoie, Kim, additional, Stöhr, Wolfgang, additional, Lelièvre, Jean-Daniel, additional, Bart, Pierre-Alexandre, additional, Launay, Odile, additional, Weber, Jonathan, additional, Salzberger, Bernd, additional, Wiedemann, Aurélie, additional, Surenaud, Mathieu, additional, Koelle, David M., additional, Wolf, Hans, additional, Wagner, Ralf, additional, Rieux, Véronique, additional, Montefiori, David C., additional, Yates, Nicole L., additional, Tomaras, Georgia D., additional, Gottardo, Raphael, additional, Mayer, Bryan, additional, Ding, Song, additional, Thiébaut, Rodolphe, additional, McCormack, Sheena, additional, Chêne, Geneviève, additional, and Pantaleo, Giuseppe, additional

Published
2020
Full Text
View/download PDF

38. Immune alterations during SARS-CoV-2-related acute respiratory distress syndrome

Author

Bouadma, Lila, primary, Wiedemann, Aurélie, additional, Patrier, Juliette, additional, Surénaud, Mathieu, additional, Wicky, Paul-Henri, additional, Foucat, Emile, additional, Diehl, Jean-Luc, additional, Hejblum, Boris P., additional, Sinnah, Fabrice, additional, Montmollin, Etienne de, additional, Lacabaratz, Christine, additional, Thiébaut, Rodolphe, additional, Timsit, JF, additional, and Lévy, Yves, additional

Published
2020
Full Text
View/download PDF

40. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals

Author

Thiébaut, Rodolphe, Hejblum, Boris P., Hocini, Hakim, Bonnabau, Henri, Skinner, Jason, Montes, Monica, Lacabaratz, Christine, Richert, Laura, Palucka, Karolina, Banchereau, Jacques, Lévy, Yves, Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Baylor Institute for Immunology Research (BIIR), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), This study was supported by a grant from the Agence Nationale de Recherches sur le SIDA et les hépatites virales(ANRS). LR received a Ph.D. scholarship financed by Sidaction. This work was supported by the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77-01 funding the Vaccine ResearchInstitute (VRI)., Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), and Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, HIV Antigens, dendritic cell, Immunology, HIV Infections, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Immunology and Allergy, Humans, Original Research, AIDS Vaccines, Blood Cells, Gene Expression Profiling, Vaccination, Computational Biology, HIV, systems biology, Dendritic Cells, Middle Aged, Viral Load, Texas, SISTM, Patient Outcome Assessment, Host-Pathogen Interactions, HIV-1, gene expression, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, therapeutic vaccine, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Transcriptome, antiretroviral therapy interruption
Abstract

International audience; The goal of HIV therapeutic vaccination is to induce HIV-specific immune response able to control HIV replication. We previously reported that vaccination with ex vivo generated Dendritic Cells (DC) loaded with HIV-lipopeptides in HIV-infected patients (n = 19) on antiretroviral therapy (ART) was well-tolerated and immunogenic. Vaccine-elicited HIV-specific T cell responses were associated with improved control of viral replication following antiretroviral interruption (ATI from w24 to w48). We show an inverse relationship between HIV-specific responses (production of IL-2, IL-13, IL-21, IFN-g, CD4 polyfunctionality, i.e., production of at least two cytokines) and the peak of viral load during ATI. Here we have performed an integrative systems vaccinology analysis including: (i) post vaccination (w16) immune responses assessed by cytometry, cytokine secretion, and Interferon-γ ELISPOT assays; (ii) whole blood and cellular gene expression measured during vaccination; and (iii) viral parameters following ATI, with the objective to disentangle the relationships between these markers and to identify vaccine signatures. During vaccination, 69 gene expression modules out of 260 varied significantly including (by order of significance) modules related to inflammation (Chaussabel Modules M3.2, M4.13, M4.6, M5.7, M7.1, M4.2), plasma cells (M4.11) and T cells (M4.1, 4.15). Cellular immune responses were positively correlated to genes belonging to T cell functional modules (M4.1, M4.15) at w16 and negatively correlated to genes belonging to inflammation modules (M7.1, M5.7, M3.2, M4.13, M4.2). More specifically, we show that prolonged increased abundance of inflammatory gene pathways related to toll-like receptor signaling (especially TLR4) are associated with both lower vaccine immune responses and control of viral replication post ATI. Further comparison of DC vaccine gene signatures with previously reported non-HIV vaccine signatures, such as flu and pneumococcal vaccines, revealed common pathways across vaccines. Overall, these results show that too long duration and too high intensity of vaccine inflammatory responses hamper the magnitude of effector responses. [ABSTRACT FROM AUTHOR] Copyright of Frontiers in Immunology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.

Published
2019

42. T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines(MVA HIV-B; LIPO-5; GTU-MultiHIV B)-ANRS/INSERM VRI01 Trial

Author

Richert, Laura, Wiedemann, Aurelie, Launay, Odile, Lucht, Frederic, Poizot-Martin, Isabelle, Lacabaratz, Christine, Hocini, Hakim, Lhomme, Edouard, Bauduin, Claire, Surenaud, Mathieu, Guillaumat, Lydia, Lefebvre, Cécile, Hardel, Lucile, Rieux, Véronique, Delahaye, Solenne, Rouch, Elodie, Reijonen, Kalevi, Levy, Yves, Thiébaut, Rodolphe, Lelievre, Jean-Daniel, Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Bordeaux [Bordeaux], FIT Biotech Ltd. [Tampere], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP)-Groupe hospitalier Broca-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Institut National de la Santé et de la Recherche Médicale (INSERM), and Admin, Oskar

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MORPH3Eus, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS, SISTM
Abstract

International audience

Published
2018

43. Lancet

Author

Levy, Yves, Lane, Clifford, Piot, Peter, Beavogui, Abdul Habib, Kieh, Mark, Leigh, Bailah, Doumbia, Seydou, D’Ortenzio, Eric, Levy Marchal, Claire, Pierson, Jérôme, Watson-Jones, Deborah, Nguyen, Vinh-Kim, Larson, Heidi, Lysander, Julia, Lacabaratz, Christine, Thiébaut, Rodolphe, Augier, Augustin, Ishola, David, Kennedy, Stephen, Chene, Geneviève, Greenwood, Brian, Neaton, James, Yazdanpanah, Yazdan, Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), London School of Hygiene and Tropical Medicine (LSHTM), Centre National de Formation et de Recherche en Santé Rurale [Maférinyah, Guinée] (CNFRSR), PREVAIL, University of Sierra Leone (USL), Université des sciences, des techniques et des technologies de Bamako (USTTB), Institut de hautes études internationales et du développement (IHEID), University of Geneva [Switzerland], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Alliance for International medical Action (ALIMA), University of Minnesota Medical School, University of Minnesota System, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), and Université de Genève = University of Geneva (UNIGE)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, mORPH3Eus, ComputingMilieux_MISCELLANEOUS, SISTM
Abstract

International audience

Published
2018

44. Long-lasting severe immune dysfunction in Ebola virus disease survivors

Author

Wiedemann, Aurélie, primary, Foucat, M.Sc. Emile, additional, Hocini, Hakim, additional, Lefebvre, M.Sc. Cécile, additional, Keita, Alpha Kabinet, additional, Ayouba, Ahidjo, additional, Mély, M.Sc. Stéphane, additional, Fernandez, M.Sc. José-Carlos, additional, Tou, Abdoulaye, additional, Lévy-Marchal, Claire, additional, Raoul, Hervé, additional, Delaporte, Eric, additional, Koivogui, Lamine, additional, Lacabaratz, Christine, additional, and Lévy, Yves, additional

Published
2019
Full Text
View/download PDF

46. HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood

Author

Hocini, Hakim, primary, Bonnabau, Henri, additional, Lacabaratz, Christine, additional, Lefebvre, Cécile, additional, Tisserand, Pascaline, additional, Foucat, Emile, additional, Lelièvre, Jean-Daniel, additional, Lambotte, Olivier, additional, Saez–Cirion, Asier, additional, Versmisse, Pierre, additional, Thiébaut, Rodolphe, additional, and Lévy, Yves, additional

Published
2019
Full Text
View/download PDF

47. Serum ST2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aquitaine Cohort, France

Author

Thiebaut, Rodolphe, Hue, Sophie, Le Marec, Fabien, Lelievre, Jean-Daniel, Dupon, Michel, Foucat, Emile, Lazaro, Estibaliz, Dabis, Francois, Duffau, Pierre, Wittkop, Linda, Surénaud, Mathieu, Pellegrin, Isabelle, Lacabaratz, Christine, Bonnet, Fabrice, Lévy, Yves, Avalos, Marta, Université de Bordeaux (UB), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'immunologie et d'immunogénétique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Service des maladies infectieuses, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service de médecine interne et maladies tropicales, CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Service de médecine interne et maladies infectieuses [Bordeaux], Epidémiologie et Biostatistique [Bordeaux], and Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

International audience; OBJECTIVE:To evaluate the predictive value of soluble suppression of tumorigenicity 2 (sST2), a decoy receptor of IL-33 involved in several inflammatory and immune diseases, for death in HIV infection.DESIGN:Patients enrolled in the ANRS CO3 Aquitaine Cohort, a prospective hospital-based cohort of HIV-1-infected patients, who had a plasma sample available in the biobank were systematically eligible.METHODS:sST2, soluble CD14 (sCD14) and IL-6 were measured using Luminex multiplex bead-based technology (R&D Systems) and a Bio-Plex 200 instrument (BioRad). Predictive capacities of sST2, sCD14, IL-6 and of the Veterans Aging Cohort Study clinical score at baseline on overall mortality were compared using multivariable Cox proportional hazards models.RESULTS:During a median follow-up of 7.2 years [interquartile range (IQR): 6.0; 7.9], 93 deaths from all causes (incidence rate 9.9 per 1000 patient-years; 95% confidence interval 7.9-11.9) were reported in 1414 patients. The median sST2 baseline concentration was 22.9 ng/ml (IQR: 17.7; 30.3) and was higher (30.8 ng/ml, IQR: 21.5; 42.1) in patients who died as compared with those who stayed alive (22.6 ng/ml; IQR: 17.5; 29.6) (P

Published
2017

48. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates

Author

Flamar, Anne-Laure, primary, Bonnabau, Henri, additional, Zurawski, Sandra, additional, Lacabaratz, Christine, additional, Montes, Monica, additional, Richert, Laura, additional, Wiedemann, Aurelie, additional, Galmin, Lindsey, additional, Weiss, Deborah, additional, Cristillo, Anthony, additional, Hudacik, Lauren, additional, Salazar, Andres, additional, Peltekian, Cécile, additional, Thiebaut, Rodolphe, additional, Zurawski, Gerard, additional, and Levy, Yves, additional

Published
2018
Full Text
View/download PDF

49. Prevention of Ebola virus disease through vaccination: where we are in 2018

Author

Lévy, Yves, primary, Lane, Clifford, additional, Piot, Peter, additional, Beavogui, Abdul Habib, additional, Kieh, Mark, additional, Leigh, Bailah, additional, Doumbia, Seydou, additional, D'Ortenzio, Eric, additional, Lévy-Marchal, Claire, additional, Pierson, Jerome, additional, Watson-Jones, Deborah, additional, Nguyen, Vinh-Kim, additional, Larson, Heidi, additional, Lysander, Julia, additional, Lacabaratz, Christine, additional, Thiebaut, Rodolphe, additional, Augier, Augustin, additional, Ishola, David, additional, Kennedy, Stephen, additional, Chêne, Geneviève, additional, Greenwood, Brian, additional, Neaton, James, additional, and Yazdanpanah, Yazdan, additional

Published
2018
Full Text
View/download PDF

50. Additional file 3: of Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells

Author

Surenaud, Mathieu, Manier, Céline, Richert, Laura, Thiébaut, Rodolphe, Levy, Yves, Hue, Sophie, and Lacabaratz, Christine

Subjects
hemic and immune systems
Abstract

PBMC viability over 7 days of culture. PBMC Viability (%) from one healthy donor for two different experiments was determined by Acridine Orange/Propidium iodide (AOPI) staining with Auto 2000 cellometer (Nexcelom) with NS-, PPD (1 μg/ml)-, or SEB (10 or 100 ng/ml)-stimulated PBMC for 1 to 7 days. (PDF 184 kb)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results